Monoclonal Antibody Therapeutics Market by Source (Chimeric, Human, Humanized), End User (Hospitals, Private Clinics, Research Institute), Application - Global Forecast 2024-2030


Attention: There is an updated edition available for this report.

Monoclonal Antibody Therapeutics Market by Source (Chimeric, Human, Humanized), End User (Hospitals, Private Clinics, Research Institute), Application - Global Forecast 2024-2030


The Monoclonal Antibody Therapeutics Market size was estimated at USD 158.91 billion in 2023 and expected to reach USD 178.77 billion in 2024, at a CAGR 12.59% to reach USD 364.53 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Monoclonal Antibody Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Monoclonal Antibody Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Monoclonal Antibody Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., Bayer AG, Biogen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Envigo, F. Hoffmann-La Roche Ltd, GenScript, GlaxoSmithKline Plc, Johnson & Johnson, Merck Sharp & Dohme Corp.,, Novartis International AG, Pfizer Inc, and Sanofi S.A.

Market Segmentation & Coverage

This research report categorizes the Monoclonal Antibody Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

Source

Chimeric

Human

Humanized
End User

Hospitals

Private Clinics

Research Institute
Application

Autoimmune Diseases

Cancer

Hematological Diseases

Infectious Diseases

Ophthalmological Diseases
Region

Americas
Argentina
Brazil
Canada
Mexico
United States

California

Florida

Illinois

New York

Ohio

Pennsylvania

Texas

Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam

Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Monoclonal Antibody Therapeutics Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Monoclonal Antibody Therapeutics Market?
3. What are the technology trends and regulatory frameworks in the Monoclonal Antibody Therapeutics Market?
4. What is the market share of the leading vendors in the Monoclonal Antibody Therapeutics Market?
5. Which modes and strategic moves are suitable for entering the Monoclonal Antibody Therapeutics Market?

Note: PDF & Excel + Online Access - 1 Year


1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Monoclonal Antibody Therapeutics Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing adoption of monoclonal antibody therapeutics in cancer treatments
5.1.1.2. Increasing approvals of monoclonal antibodies
5.1.1.3. Rising use of monoclonal antibodies for the treatment of autoimmune diseases
5.1.2. Restraints
5.1.2.1. High cost of clinical research and development
5.1.3. Opportunities
5.1.3.1. Increasing product launches and investment in R&D
5.1.3.2. Increasing regulatory support for the treatment of rare diseases
5.1.4. Challenges
5.1.4.1. Variation in results from patient to patient
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Monoclonal Antibody Therapeutics Market, by Source
6.1. Introduction
6.2. Chimeric
6.3. Human
6.4. Humanized
7. Monoclonal Antibody Therapeutics Market, by End User
7.1. Introduction
7.2. Hospitals
7.3. Private Clinics
7.4. Research Institute
8. Monoclonal Antibody Therapeutics Market, by Application
8.1. Introduction
8.2. Autoimmune Diseases
8.3. Cancer
8.4. Hematological Diseases
8.5. Infectious Diseases
8.6. Ophthalmological Diseases
9. Americas Monoclonal Antibody Therapeutics Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Monoclonal Antibody Therapeutics Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Monoclonal Antibody Therapeutics Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. AbbVie Inc.
13.1.2. Amgen Inc.
13.1.3. Bayer AG
13.1.4. Biogen Inc.
13.1.5. Bristol-Myers Squibb Company
13.1.6. Eli Lilly and Company
13.1.7. Envigo
13.1.8. F. Hoffmann-La Roche Ltd
13.1.9. GenScript
13.1.10. GlaxoSmithKline Plc
13.1.11. Johnson & Johnson
13.1.12. Merck Sharp & Dohme Corp.,
13.1.13. Novartis International AG
13.1.14. Pfizer Inc
13.1.15. Sanofi S.A
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
FIGURE 1. MONOCLONAL ANTIBODY THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 2. MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2023 VS 2030
FIGURE 3. MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. MONOCLONAL ANTIBODY THERAPEUTICS MARKET DYNAMICS
FIGURE 7. MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2023 VS 2030 (%)
FIGURE 8. MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 10. MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 12. MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. MONOCLONAL ANTIBODY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. MONOCLONAL ANTIBODY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings